Roche Buys Obesity Drug Maker Carmot for $3.1B
Though Carmot’s drugs are still in early stages of development, the deal could lead to a competitor to the likes of Eli Lilly & Co.’s Zepbound.
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
